MTOR and hepatocellular carcinoma: Currently, targeted therapy, such as anti-mammalian target of rapamycin (mTOR) inhibitors, and immune checkpoint blockade therapy, such as anti-programmed cell death protein 1 (PD1) inhibitors, have great potential effects against HCC (Ruiz de Galarreta et al., 2019; Wang et al., 2019).